Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891694686> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2891694686 endingPage "2576" @default.
- W2891694686 startingPage "2576" @default.
- W2891694686 abstract "2576 Background: DPYD gene encodes DPD, the rate-limiting enzyme responsible for catabolism of 5-FU and is responsible for > 85% of 5-FU elimination. Deficiency of DPD due to DPYD polymorphism gives rise to severe 5-FU AEs from reduced catabolism. This pharmacogenetic ‘DPD syndrome’ manifests typically as severe or fatal diarrhea, mucositis/stomatitis, myelosuppression and even rare toxicities, such as hepatitis, encephalopathy and acute cardiac ischemia following first or second dose of 5-FU. The most compelling reason to introduce routine DPD testing is to avoid severe AEs in pts who receive 5-FU/CAP. DPYD mutations are found in 50% of severe 5-FU toxicity cases. Methods: We analyzed all pts who were tested for DPD deficiency after excessive toxicities from 5-FU/CAP, treated for GI cancers. DPD activity was evaluated by PBMC radioassay, genotyping of DPYD, or 2-13C uracil breath test after an informed consent. Demographics of pts, grades of toxicity, chemotherapy (dose, route) and outcomes were analyzed. Results: A total of 52 pts with DPD deficiency were identified [age range: 35 - 79 yrs; M:F = 1.3:1; Ethnicities: Caucasian (≥ 60%), African-American, unknown, Asian]. Most commonly used regimens in decreasing order were infusion 5-FU, CAP and bolus. Excessive AEs included mucositis (70%), diarrhea (40%), cytopenias (40%), nausea/vomiting (30%), HFS or skin rashes (20%), neurotoxicity (12%) and cardiotoxicity (5%). 11/12 pts had low DPD activity (range:0.064 – 0.18nmol/min/mg). DPYD genotyping showed: IVS14 + 1 G > A (c.1905+1 G > A, rs3918290) 38%, D949V (c.2846A > T, rs67376798) 21%, C29R (rs1801265) 4%, and Y186C (rs115232898, c.557 A > G) 2%. UraBT confirmed DPD deficiency in 2 pts: DOB50 of 49.4% and 52.5%. Re-challenge with CAP in 5 pts resulted in atypical or similar AE. 6 pts received vistogard; 5 recovered. 3 pts died due to AEs. Conclusions: DPYD genotyping (+ TYMS) may identify ≥ 50% of pts, who are at greatest risk of AEs. At present, no formal recommendations regarding testing for DPYD exist except warning on FDA website and prescription inserts. Our data mandates the need for prospective studies to develop guidelines in pts receiving 5-FU/CAP." @default.
- W2891694686 created "2018-09-27" @default.
- W2891694686 creator A5034905216 @default.
- W2891694686 creator A5057281188 @default.
- W2891694686 creator A5059060277 @default.
- W2891694686 creator A5064038800 @default.
- W2891694686 creator A5070961992 @default.
- W2891694686 creator A5081863364 @default.
- W2891694686 date "2018-05-20" @default.
- W2891694686 modified "2023-09-26" @default.
- W2891694686 title "Dihydropyrimidine dehydrogenase gene (<i>DPYD</i>) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades." @default.
- W2891694686 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.2576" @default.
- W2891694686 hasPublicationYear "2018" @default.
- W2891694686 type Work @default.
- W2891694686 sameAs 2891694686 @default.
- W2891694686 citedByCount "3" @default.
- W2891694686 countsByYear W28916946862021 @default.
- W2891694686 countsByYear W28916946862022 @default.
- W2891694686 crossrefType "journal-article" @default.
- W2891694686 hasAuthorship W2891694686A5034905216 @default.
- W2891694686 hasAuthorship W2891694686A5057281188 @default.
- W2891694686 hasAuthorship W2891694686A5059060277 @default.
- W2891694686 hasAuthorship W2891694686A5064038800 @default.
- W2891694686 hasAuthorship W2891694686A5070961992 @default.
- W2891694686 hasAuthorship W2891694686A5081863364 @default.
- W2891694686 hasConcept C104317684 @default.
- W2891694686 hasConcept C121608353 @default.
- W2891694686 hasConcept C123321153 @default.
- W2891694686 hasConcept C126322002 @default.
- W2891694686 hasConcept C135763542 @default.
- W2891694686 hasConcept C185592680 @default.
- W2891694686 hasConcept C197934379 @default.
- W2891694686 hasConcept C2776694085 @default.
- W2891694686 hasConcept C2777909004 @default.
- W2891694686 hasConcept C2778050828 @default.
- W2891694686 hasConcept C2778496288 @default.
- W2891694686 hasConcept C2778715236 @default.
- W2891694686 hasConcept C2779655350 @default.
- W2891694686 hasConcept C2780456651 @default.
- W2891694686 hasConcept C2780580376 @default.
- W2891694686 hasConcept C29730261 @default.
- W2891694686 hasConcept C526805850 @default.
- W2891694686 hasConcept C55493867 @default.
- W2891694686 hasConcept C55775858 @default.
- W2891694686 hasConcept C71924100 @default.
- W2891694686 hasConcept C90924648 @default.
- W2891694686 hasConcept C98274493 @default.
- W2891694686 hasConceptScore W2891694686C104317684 @default.
- W2891694686 hasConceptScore W2891694686C121608353 @default.
- W2891694686 hasConceptScore W2891694686C123321153 @default.
- W2891694686 hasConceptScore W2891694686C126322002 @default.
- W2891694686 hasConceptScore W2891694686C135763542 @default.
- W2891694686 hasConceptScore W2891694686C185592680 @default.
- W2891694686 hasConceptScore W2891694686C197934379 @default.
- W2891694686 hasConceptScore W2891694686C2776694085 @default.
- W2891694686 hasConceptScore W2891694686C2777909004 @default.
- W2891694686 hasConceptScore W2891694686C2778050828 @default.
- W2891694686 hasConceptScore W2891694686C2778496288 @default.
- W2891694686 hasConceptScore W2891694686C2778715236 @default.
- W2891694686 hasConceptScore W2891694686C2779655350 @default.
- W2891694686 hasConceptScore W2891694686C2780456651 @default.
- W2891694686 hasConceptScore W2891694686C2780580376 @default.
- W2891694686 hasConceptScore W2891694686C29730261 @default.
- W2891694686 hasConceptScore W2891694686C526805850 @default.
- W2891694686 hasConceptScore W2891694686C55493867 @default.
- W2891694686 hasConceptScore W2891694686C55775858 @default.
- W2891694686 hasConceptScore W2891694686C71924100 @default.
- W2891694686 hasConceptScore W2891694686C90924648 @default.
- W2891694686 hasConceptScore W2891694686C98274493 @default.
- W2891694686 hasIssue "15_suppl" @default.
- W2891694686 hasLocation W28916946861 @default.
- W2891694686 hasOpenAccess W2891694686 @default.
- W2891694686 hasPrimaryLocation W28916946861 @default.
- W2891694686 hasRelatedWork W1989511857 @default.
- W2891694686 hasRelatedWork W2047969495 @default.
- W2891694686 hasRelatedWork W2181760275 @default.
- W2891694686 hasRelatedWork W2182963545 @default.
- W2891694686 hasRelatedWork W2317376769 @default.
- W2891694686 hasRelatedWork W2412069692 @default.
- W2891694686 hasRelatedWork W2804440574 @default.
- W2891694686 hasRelatedWork W2891694686 @default.
- W2891694686 hasRelatedWork W2945826264 @default.
- W2891694686 hasRelatedWork W4293229929 @default.
- W2891694686 hasVolume "36" @default.
- W2891694686 isParatext "false" @default.
- W2891694686 isRetracted "false" @default.
- W2891694686 magId "2891694686" @default.
- W2891694686 workType "article" @default.